Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
This bill clarifies that under section 340B of the Public Health Service Act drug manufacturers must offer discounted prices to covered entities regardless of the manner or location in which drugs are dispensed, including when covered entities use contract pharmacies. It prohibits manufacturers from placing certain conditions on covered entities’ ability to purchase or use covered outpatient drugs at or below the ceiling price (with limited discretion for the Secretary), and explicitly extends these requirements to contract pharmacy arrangements.
Appropriate scope and size of enforcement: liberals favor strong penalties to deter manufacturer restrictions; conservatives see daily $2M fines as excessive and overreaching.
Relative to its intended legislative type, this bill is a focused statutory amendment that clearly defines goals and provides concrete legal mechanisms and penalties, while relying on the Secretary to fill in regulatory detail.
This bill clarifies that under section 340B of the Public Health Service Act drug manufacturers must offer discounted prices to covered entities regardless of the manner or location in which drugs are dispensed, including when covered entities use contract pharmacies.
It prohibits manufacturers from placing certain conditions on covered entities’ ability to purchase or use covered outpatient drugs at or below the ceiling price (with limited discretion for the Secretary), and explicitly extends these requirements to contract pharmacy arrangements.
The bill adds statutory civil monetary penalties (up to $2,000,000 per day) for intentional violations of the new prohibitions and directs the Secretary of HHS to promulgate implementing regulations within 180 days, including standards for penalties and a process for covered entities to assert claims of violations.
On content alone, the bill addresses an important, narrow programmatic issue (access under 340B) which helps its chances relative to sweeping reform. However, it also creates a potent enforcement regime and removes certain manufacturer levers, triggering strong countervailing incentives for industry opposition and litigation. The lack of compromise mechanisms (sunset, pilots, phased approach) and the sizable potential penalties reduce near-term prospects for enactment unless incorporated into a larger negotiated package or significantly amended.
Relative to its intended legislative type, this bill is a focused statutory amendment that clearly defines goals and provides concrete legal mechanisms and penalties, while relying on the Secretary to fill in regulatory detail.
Appropriate scope and size of enforcement: liberals favor strong penalties to deter manufacturer restrictions; conservatives see daily $2M fines as excessive and overreaching.
These are examples from the analysis, not a ranked list of the most-affected groups.
Appropriate scope and size of enforcement: liberals favor strong penalties to deter manufacturer restrictions; conservatives see daily $2M fines as excessive and overreaching.
A liberal/left-leaning observer would likely view the bill positively as a reinforcement of the 340B program’s intent to help safety-net providers stretch resources and preserve patient access—especially for specialty and mail-order drugs that community providers rely on.
They would welcome the explicit prohibition on manufacturers placing restrictive conditions on contract pharmacy arrangements and the new enforcement tools, which aim to prevent manufacturers from undermining program benefits.
They would see the bill as protecting vulnerable patients and community clinics from corporate interference.
A centrist/moderate observer would recognize the bill’s goal of clarifying statutory obligations and protecting patient access under 340B, and would appreciate an effort to reduce disruption in care resulting from manufacturer-imposed restrictions.
At the same time, they would be cautious about the very large daily civil monetary penalty in the bill and the potential for aggressive enforcement to provoke litigation or unintended supply consequences.
Centrists would want clearer regulatory standards, a fair administrative process including appeal rights, and calibrated penalties that deter bad actors without being punitive beyond reason.
A mainstream conservative observer would likely view the bill skeptically as an expansion of federal regulatory authority over private business practices and contractual freedom between manufacturers and distributors.
They would be concerned that the bill interferes with manufacturers’ ability to set conditions to protect supply chains, ensure patient safety, or negotiate business arrangements, and that the large statutory penalties create excessive federal coercion.
Conservatives would worry about downstream effects like higher drug prices, reduced product availability, or manufacturers limiting sales to certain channels—outcomes they would see as harmful to consumers and markets.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill addresses an important, narrow programmatic issue (access under 340B) which helps its chances relative to sweeping reform. However, it also creates a potent enforcement regime and removes certain manufacturer levers, triggering strong countervailing incentives for industry opposition and litigation. The lack of compromise mechanisms (sunset, pilots, phased approach) and the sizable potential penalties reduce near-term prospects for enactment unless incorporated into a larger negotiated package or significantly amended.
The bill has not accumulated any surfaced votes yet.
Appropriate scope and size of enforcement: liberals favor strong penalties to deter manufacturer restrictions; conservatives see daily $2M…
On content alone, the bill addresses an important, narrow programmatic issue (access under 340B) which helps its chances relative to sweepi…
Relative to its intended legislative type, this bill is a focused statutory amendment that clearly defines goals and provides concrete legal mechanisms and penalties, while relying on the Secretary to fill in regulatory…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.